Li Tao1, Laura Chu2, Lisa I Wang2, Lisa Moy3, Melissa Brammer2, Chunyan Song2, Marjorie Green2, Allison W Kurian4,5, Scarlett L Gomez3,4,5, Christina A Clarke3,4,5. 1. Cancer Prevention Institute of California, Fremont, CA, USA. li.tao@cpic.org. 2. Genentech, Inc., San Francisco, CA, USA. 3. Cancer Prevention Institute of California, Fremont, CA, USA. 4. Departments of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 5. Departments of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA.
Abstract
PURPOSE: To examine the occurrence and outcomes of de novo metastatic (Stage IV) breast cancer, particularly with respect to tumor HER2 expression. METHODS: We studied all 6,268 de novo metastatic breast cancer cases diagnosed from 1 January 2005 to 31 December 2011 and reported to the California Cancer Registry. Molecular subtypes were classified according to HER2 and hormone receptor (HR, including estrogen and/or progesterone receptor) expression. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) of Stage IV versus Stage I-III breast cancer; Cox proportional hazards regression was used to assess relative hazard (RH) of mortality. RESULTS: Five percent of invasive breast cancer was metastatic at diagnosis. Compared to patients with earlier stage disease, patients with de novo metastatic disease were significantly more likely to have HER2+ tumors (HR+/HER2+: OR 1.29, 95 % CI 1.17-1.42; HR-/HER2+: OR 1.40, 95 %CI 1.25-1.57, vs. HR+/HER2-). Median survival improved over time, but varied substantially across race/ethnicity (Asians: 34 months; African Americans: 6 months), neighborhood socioeconomic status (SES) (highest: 34 months, lowest: 20 months), and molecular subtype (HR+/HER2+: 45 months; triple negative: 12 months). In a multivariable model, triple negative (RH 2.85, 95 % CI 2.50-3.24) and HR-/HER2+ (RH 1.60, 95 % CI 1.37-1.87) had worse, while HR+/HER2+ had similar, risk of all-cause death compared to HR+/HER2- breast cancer. CONCLUSIONS: De novo metastatic breast cancer was more likely to be HER2+. Among metastatic tumors, those that were HER2+ had better survival than other subtypes.
PURPOSE: To examine the occurrence and outcomes of de novo metastatic (Stage IV) breast cancer, particularly with respect to tumorHER2 expression. METHODS: We studied all 6,268 de novo metastatic breast cancer cases diagnosed from 1 January 2005 to 31 December 2011 and reported to the California Cancer Registry. Molecular subtypes were classified according to HER2 and hormone receptor (HR, including estrogen and/or progesterone receptor) expression. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) of Stage IV versus Stage I-III breast cancer; Cox proportional hazards regression was used to assess relative hazard (RH) of mortality. RESULTS: Five percent of invasive breast cancer was metastatic at diagnosis. Compared to patients with earlier stage disease, patients with de novo metastatic disease were significantly more likely to have HER2+ tumors (HR+/HER2+: OR 1.29, 95 % CI 1.17-1.42; HR-/HER2+: OR 1.40, 95 %CI 1.25-1.57, vs. HR+/HER2-). Median survival improved over time, but varied substantially across race/ethnicity (Asians: 34 months; African Americans: 6 months), neighborhood socioeconomic status (SES) (highest: 34 months, lowest: 20 months), and molecular subtype (HR+/HER2+: 45 months; triple negative: 12 months). In a multivariable model, triple negative (RH 2.85, 95 % CI 2.50-3.24) and HR-/HER2+ (RH 1.60, 95 % CI 1.37-1.87) had worse, while HR+/HER2+ had similar, risk of all-cause death compared to HR+/HER2- breast cancer. CONCLUSIONS: De novo metastatic breast cancer was more likely to be HER2+. Among metastatic tumors, those that were HER2+ had better survival than other subtypes.
Entities:
Keywords:
De novo metastatic breast cancer; Subtype
Authors: Hsiao-Ching Huang; Mary H Smart; Ashwini Zolekar; Huiwen Deng; Colin C Hubbard; Kent F Hoskins; Naomi Y Ko; Jenny S Guadamuz; Gregory S Calip Journal: Breast Cancer Res Treat Date: 2022-04-23 Impact factor: 4.872
Authors: Anushri Chitkara; Ines Mesa-Eguiagaray; Sarah H Wild; Peter S Hall; David A Cameron; Andrew H Sims; Jonine D Figueroa Journal: Breast Cancer Res Treat Date: 2022-09-18 Impact factor: 4.624
Authors: Li Tao; Richard B Schwab; Yazmin San Miguel; Scarlett Lin Gomez; Alison J Canchola; Manuela Gago-Dominguez; Ian K Komenaka; James D Murphy; Alfredo A Molinolo; Maria Elena Martinez Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-17 Impact factor: 4.254
Authors: Jennifer L Caswell-Jin; Alison Callahan; Natasha Purington; Summer S Han; Haruka Itakura; Esther M John; Douglas W Blayney; George W Sledge; Nigam H Shah; Allison W Kurian Journal: JCO Clin Cancer Inform Date: 2021-05
Authors: Jennifer K Plichta; Samantha M Thomas; Amanda R Sergesketter; Rachel A Greenup; Laura H Rosenberger; Oluwadamilola M Fayanju; Gretchen Kimmick; Jeremy Force; Terry Hyslop; E Shelley Hwang Journal: Ann Surg Date: 2022-04-01 Impact factor: 13.787
Authors: Amanda Parkes; Katherine Clifton; Aydah Al-Awadhi; Oluchi Oke; Carla L Warneke; Jennifer K Litton; Gabriel N Hortobagyi Journal: NPJ Breast Cancer Date: 2018-01-25